The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.
The Center for Biosimilars® has launched “Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline,” an e-book resource for the health care community. This publication contains insightful analysis and guidance from key opinion leaders who are actively engaged in the day-to-day effort to understand biosimilar trends and bring these lower-cost agents to patients who need them.
“Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline,” answers some of the most basic and common questions about these important agents: How should the patient-physician conversation about these agents be addressed? What biosimilars are available, and in what disease categories will they be available next? Have biosimilars been accepted, and what roadmap should a health care institution follow to achieve greater biosimilar savings and access for patients? And finally, where did biosimilars come from? What was the legislative intent and regulatory foundation that led to the development of an approval pathway for these copy biologics?
Biosimilars are approved by regulators as safe and efficacious versions of originator biologics with no clinically meaningful differences. Their acceptance and use in the United States and Europe has grown rapidly, and the number of companies worldwide that are joining the effort to produce these more-economical agents bodes well for efforts to bring down the soaring cost of biologics. Biosimilars accounted for $2.2 billion of savings on health care costs in the United States in 2019, according to the Association for Accessible Medicines. There is potential for even greater savings.
Indeed, as stated recently by Dan Kistner, group senior vice president for Pharmacy Solutions at Vizient, “One of the keys to managing costs for health systems is the adoption of biosimilars as they come on the market. There are now 12 biosimilars available and where there are 2 or more competitors, we have seen prices as much as 30% lower than the branded product. Providers and payers must now become better aligned to realize the full benefit that competition can offer in driving down the cost of care.”
“Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline” is chock-full of helpful information for the health care provider, patient advocate, practice administrator, or industry professional who needs to keep up with developments in biosimilars or employ them for greater savings and access. Obtain your copy by clicking here.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.